JP2024538706A5 - - Google Patents
Info
- Publication number
- JP2024538706A5 JP2024538706A5 JP2024520924A JP2024520924A JP2024538706A5 JP 2024538706 A5 JP2024538706 A5 JP 2024538706A5 JP 2024520924 A JP2024520924 A JP 2024520924A JP 2024520924 A JP2024520924 A JP 2024520924A JP 2024538706 A5 JP2024538706 A5 JP 2024538706A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- monomer
- construct
- terminus
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163253893P | 2021-10-08 | 2021-10-08 | |
| US63/253,893 | 2021-10-08 | ||
| US202263328525P | 2022-04-07 | 2022-04-07 | |
| US63/328,525 | 2022-04-07 | ||
| PCT/US2022/077690 WO2023060188A1 (en) | 2021-10-08 | 2022-10-06 | Activatable cytokine constructs and combination methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024538706A JP2024538706A (ja) | 2024-10-23 |
| JP2024538706A5 true JP2024538706A5 (https=) | 2025-10-10 |
Family
ID=84272320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520924A Pending JP2024538706A (ja) | 2021-10-08 | 2022-10-06 | 活性化可能サイトカイン構成体及び併用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230192798A1 (https=) |
| EP (1) | EP4412635A1 (https=) |
| JP (1) | JP2024538706A (https=) |
| KR (1) | KR20240099172A (https=) |
| AU (1) | AU2022360371A1 (https=) |
| CA (1) | CA3233707A1 (https=) |
| IL (1) | IL311972A (https=) |
| MX (1) | MX2024004301A (https=) |
| TW (1) | TW202334185A (https=) |
| WO (1) | WO2023060188A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024353718A1 (en) * | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| WO2025195306A1 (en) * | 2024-03-16 | 2025-09-25 | Vibrant Pharma Limited | Multispecific antigen-binding proteins and uses thereof |
| CN120932734B (zh) * | 2025-10-13 | 2026-01-30 | 良渚实验室 | 利用中介序列msa与扩散掩码机制的肽序列生成模型及生成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0279862B1 (en) | 1986-08-28 | 1993-11-03 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20060024272A1 (en) | 2004-07-29 | 2006-02-02 | Large Scale Biology Corporation | C-terminally truncated interferon |
| RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
| AU2010215761B2 (en) | 2009-02-23 | 2017-04-06 | Cytomx Therapeutics, Inc | Proproteins and methods of use thereof |
| US9487590B2 (en) | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| NZ718283A (en) | 2013-09-25 | 2022-05-27 | Cytomx Therapeutics Inc | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| US9562073B2 (en) | 2014-01-31 | 2017-02-07 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| DK3215528T3 (da) | 2014-11-06 | 2019-10-07 | Hoffmann La Roche | Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| JP2020528878A (ja) * | 2017-06-20 | 2020-10-01 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | がん治療用インターフェロンプロドラッグ |
| CA3120327A1 (en) | 2018-12-06 | 2020-06-11 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| MX2022005666A (es) * | 2019-11-14 | 2022-10-07 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
| BR112023018735A2 (pt) * | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
-
2022
- 2022-10-06 TW TW111138099A patent/TW202334185A/zh unknown
- 2022-10-06 MX MX2024004301A patent/MX2024004301A/es unknown
- 2022-10-06 IL IL311972A patent/IL311972A/en unknown
- 2022-10-06 WO PCT/US2022/077690 patent/WO2023060188A1/en not_active Ceased
- 2022-10-06 KR KR1020247011973A patent/KR20240099172A/ko active Pending
- 2022-10-06 JP JP2024520924A patent/JP2024538706A/ja active Pending
- 2022-10-06 EP EP22809608.7A patent/EP4412635A1/en active Pending
- 2022-10-06 AU AU2022360371A patent/AU2022360371A1/en active Pending
- 2022-10-06 US US17/938,536 patent/US20230192798A1/en not_active Abandoned
- 2022-10-06 CA CA3233707A patent/CA3233707A1/en active Pending
-
2024
- 2024-01-25 US US18/423,006 patent/US20250026801A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024538706A5 (https=) | ||
| Ashkenazi et al. | Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. | |
| US12152060B2 (en) | Interleukin-2 variants and methods of uses thereof | |
| JP7682150B2 (ja) | プロテアーゼ活性化治療剤を含む組成物および方法 | |
| JP2024153643A5 (https=) | ||
| EP0617126B1 (en) | Polypeptide capable of inhibiting the binding between human IL-6 and its receptor | |
| AU2002324625B2 (en) | Interleukin-1 receptors in the treatment of diseases | |
| KR20220034115A (ko) | 암 치료용 신규한 인터루킨-2 변이체 | |
| JP7729778B2 (ja) | Ｆｍｓ様チロシンキナーゼ３（ｆｌｔ３）に対するキメラタンパク質およびキメラタンパク質複合体 | |
| RU2011138951A (ru) | Пропротеины и способы их применения | |
| US9731007B2 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| EA011992B1 (ru) | Гибридный белок антитела l19 к фибронектину ed-b и интерлейкина 12 | |
| JP2003530070A (ja) | Ｆｃ融合タンパク質としてのインターフェロン−αタンパク質の発現および搬出 | |
| KR20030048041A (ko) | 표적-특이적 프로드럭으로서 사용하기 위한항체-사이토카인-사이토카인 억제제로 이루어진 융합단백질(셀렉토카인) | |
| JP2024517871A (ja) | プロテアーゼ活性化治療剤を含む組成物および方法 | |
| JP2024511387A5 (https=) | ||
| RU2007119989A (ru) | Композиции, слитые конструкции и конъюгаты plad домена | |
| JP2018537093A5 (https=) | ||
| NZ501831A (en) | Trail binding protein (TRAIL-BP) showing significant homology to the extracellular domains of members of the tumour necrosis factor receptor (TNF-R) and is anchored to cell surface via glycosylphosphatidylinositol (GPI) linkage | |
| JP2024534062A (ja) | 誘導性サイトカインプロドラッグ及びｐｄ－１／ｐｄ－ｌ１併用療法 | |
| RU2007117716A (ru) | Химерный белок | |
| JP2024528660A (ja) | リンカーポリペプチド | |
| JP2011507498A5 (https=) | ||
| JP2013253079A (ja) | 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用 | |
| JP7544599B2 (ja) | ペプチドの血中動態改善方法 |